GSK, Merck KGaA's BTC Drug Fails for Second Time This Year

Topline data from Germany’s Merck KGaA’s Phase II INTR@PID BTC 047 study show bintrafusp alfa has single-agent efficacy and safety in the second-line treatment of locally advanced or metastatic biliary tract cancer (BTC) in patients who have either failed or are intolerant to first-line platinum-based chemotherapy.